Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
NCT ID: NCT04004793 Phase: PHASE4 Status: COMPLETED Enrollment: 328 Completion: 2023-01-31
Conditions
Type 2 Diabetes
Interventions
Intensive lifestyle intervention, Dapagliflozin 10 MG Oral Tablet, Placebo Oral Tablet
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the effect of dapagliflozin add-on intensive lifestyle intervention for remission of type 2 diabetes in obese patients with Type 2 Diabetes Mellitus. The study consists of a 12-months treatment period (in which they will receive either Dapagliflozin plus intensive lifestyle intervention or placebo plus intensive lifestyle intervention in addition to the background therapy), and a 2-month follow-up period after treatment period.
Primary Outcome
Incidence of patients with diabetes remission